A comparison of the on-treatment annualized rates of change between the “mucin-1 ≥ 2.5” group and the “mucin-1 < 2.5” group revealed that, while there was no significant between-group difference in the annualized rate of change in FVC (either including or excluding patients with AE-IPF), the annualized rate of decline in DLCO for the “mucin-1 ≥ 2.5” group was significantly greater than that of the “mucin-1 < 2.5” group, even after excluding patients with AE-IPF (Figure 5c–f). Here, MUC1 is linked to idiopathic pulmonary fibrosis.